Clinical Trial of Enterovirus 71（EV71） Inactivated Vaccine in Children Aged 36-71 Months

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

900 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-10

Study Completion Date

2019-11-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the non-inferiority of experimental EV71 vaccine compared to the control EV71 vaccine in children aged 36-71 months, to evaluate the non-inferiority of EV71 vaccine used in children aged 36-71 months compared to 6-35 months. The experimental vaccine was manufactured by Sinovac Biotech Co., Ltd, and the control vaccine was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy Trial of a Commercial EV71 Vaccine

NCT03903926

Hand, Foot and Mouth Disease

COMPLETED PHASE4

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of an EV71 Vaccine

NCT03865238

Enterovirus 71 Infection

COMPLETED PHASE3

A Study to Evaluate the Efficacy, Immunogenicity and Safety of an EV71 Vaccine in Healthy Infants and Children

NCT05099029

Enterovirus Infections

ACTIVE_NOT_RECRUITING PHASE3

Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)

NCT05107557

COVID-19

COMPLETED PHASE4

Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants

NCT01812135

Infection, Viral, Enterovirus

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a randomized, double-blind, single-center, controlled phase III clinical trial in children aged 36-71 months, and bridging trial between agegroup of 6-35 and 36-71 months. The purpose of this study is to evaluate the immunogenicity and safety of the experimental EV71 vaccine in children aged 36-71 months. The primary objective of this study is to evaluate the non-inferiority of experimental EV71 vaccine compared to the control EV71 vaccine in children aged 36-71 months, and the non-inferiority of EV71 vaccine used in children aged 36-71 months compared to 6-35 months. The secondary objective is to evaluate the safety of the experimental vaccine used in children aged 36-71 months. The experimental vaccine is manufactured by Sinovac Biotech Co., Ltd, and the control vaccine is manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences. 600 children aged 36-71 months will be randomly assigned in to receive the experimental vaccine or control vaccine, and 300 children aged 6-35 months will receive the experimental vaccine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hand, Foot and Mouth Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

36-71 months old children-experimental EV71 vaccine.

Group Type EXPERIMENTAL

36-71 months old children-experimental EV71 vaccine.

Intervention Type BIOLOGICAL

Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.

Vaccine-controlled group

36-71 months old children-control EV71 vaccine.

Group Type ACTIVE_COMPARATOR

36-71 months old children-control EV71 vaccine.

Intervention Type BIOLOGICAL

Two doses control EV71 vaccine at the 0, 30 days vaccination schedule.

Age-controlled group

6-35 months old children-experimental EV71 vaccine.

Group Type ACTIVE_COMPARATOR

6-35 months old children-experimental EV71 vaccine.

Intervention Type BIOLOGICAL

Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

36-71 months old children-experimental EV71 vaccine.

Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.

Intervention Type BIOLOGICAL

36-71 months old children-control EV71 vaccine.

Two doses control EV71 vaccine at the 0, 30 days vaccination schedule.

Intervention Type BIOLOGICAL

6-35 months old children-experimental EV71 vaccine.

Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy volunteers ≥ 2 years old;
* Proven legal identity;
* Participants or guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrolment.

Exclusion Criteria

* Prior vaccination with EV71 vaccine;
* History of hand, foot and mouth disease;
* History of allergy to any vaccine or vaccine ingredient, asthma, serious adverse reactions to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc;
* Congenital malformation, developmental disorders, genetic defects, or severe malnutrition;
* Autoimmune disease or immunodeficiency/immunosuppressive;
* Severe/uncontrollable nervous system disease (epilepsy, seizures or convulsions) or mental illness;
* History of thyroidectomy, no spleen and functional spleen;
* Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders;
* Receipt of any of the following products:

1. Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) within 6 month prior to study entry
2. Blood products within 2 months prior to study entry
3. Any other investigational products (drug or vaccine）within 30 days prior to study entry
4. Any live attenuated vaccine within 14 days prior to study entry
5. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;
* Acute disease or acute stage of chronic disease within 7 days prior to study entry;
* Axillary temperature \> 37.0 °C;
* Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators.

Minimum Eligible Age

6 Months

Maximum Eligible Age

71 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes